Biosergen AB reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was SEK 9.38 million compared to SEK 5.18 million a year ago. Net loss was SEK 27.04 million compared to SEK 39.91 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.303 SEK | -0.33% |
|
-5.02% | -65.57% |
06-14 | Biosergen AB Approves Board Changes | CI |
06-11 | Biosergen AB Receives the Final Permission Required to Test Lead Candidate BSG005 in Patients with Invasive Fungal Infection | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-65.57% | 4.11M | |
+16.49% | 122B | |
+21.73% | 116B | |
+22.18% | 27.03B | |
-21.81% | 20.36B | |
-16.89% | 16.43B | |
-18.81% | 15.91B | |
-44.74% | 15.6B | |
+62.72% | 14.94B | |
+3.09% | 13.59B |
- Stock Market
- Equities
- BIOSGN Stock
- News Biosergen AB
- Biosergen AB Reports Earnings Results for the Full Year Ended December 31, 2023